Molecular Therapy Drug Discovery
Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage
The publisher did not provide an abstract — full text is available via the link below.
Molecular Therapy Drug Discovery
The publisher did not provide an abstract — full text is available via the link below.